Responses
Clinical and epidemiological research
Extended report
Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan
Compose a Response to This Article
Other responses
No responses have been published for this article.